Related Experiment Video
Updated: Jul 16, 2025

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Effect of 4-AP on MPP+/ MPTP-induced Parkinson's disease model
Qiongwen Rong1, Chang Zhou1, Yuanyuan Ma1
1Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, 570102, China. 13907580113@163.com.
Abstract:
To study the effect of 4-AP on Parkinson's disease (PD) cells and animal model. PD cells were pretreated with different concentrations of 4-AP for 24 hours, then PD cells were prepared by MPP+, and the cell activity was detected by CCK8 kit. PD mice were prepared by MPTP and then given 4-AP for 10 days. Finally, the behavioral changes of mice were detected by pole climbing test and open field test, and the expression of TH in the midbrain was detected by IHC and WB. 4-AP could increase the activity of PD cells induced by MPP+. In the field experiment, the total spontaneous activity distance of PD mice (1380.01 ± 151.84) cm was not different from that of 4-AP intervention (1228.65 ± 358.25) cm but was reduced than that of normal mice (2121.89 ± 235.95) (P<0.05). In the pole climbing test, the pole climbing time of PD mice was (7.95 ± 1.02) seconds, compared with that of PD mice treated with 4-AP, there was no difference between the two groups, but it was reduced than that of normal mice (P<0.05). IHC and Western blot showed that the mesencephalic TH of PD mice and drug-treated mice were reduced than that of normal mice (P<0.05), however, drug intervention could not reduce the expression of TH in mice with PD (P>0.5). 4-AP pretreatment can reduce the toxic and side effects of MPP+. 4-AP can not improve the motor function impairment of PD mice, nor can it reduce the toxic effect of MPTP on dopaminergic neurons. There are differences between pre-treatment and post-intervention in the treatment of MPP+/MPTP-induced PD. In order to better explore the drug treatment and target of PD, it is hoped that a cure for PD can be found in PD animals. The timing of intervention and cell and animal experiments should complement each other.
Insights
4-Aminopyridine (4-AP) did not improve motor function in Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction.
- MPP+ and MPTP are commonly used neurotoxins to induce Parkinsonian models in vitro and in vivo.
- 4-Aminopyridine (4-AP) is a potassium channel blocker with potential neuroprotective effects.
Purpose of the Study:
- To investigate the therapeutic potential of 4-Aminopyridine (4-AP) in cellular and animal models of Parkinson's disease (PD).
- To evaluate the effect of 4-AP on cell viability, motor function, and dopaminergic neuron survival in PD models.
Main Methods:
- Parkinson's disease cell models were established using MPP+ and treated with varying concentrations of 4-AP.
- Cell viability was assessed using the CCK8 assay.
- Parkinson's disease mouse models were induced by MPTP and subsequently treated with 4-AP for 10 days.
- Behavioral tests (pole climbing, open field) and immunohistochemistry (IHC)/Western blot (WB) for tyrosine hydroxylase (TH) expression were performed.
Main Results:
- 4-AP increased the viability of MPP+-induced Parkinson's disease cells.
- In MPTP-induced Parkinson's disease mice, 4-AP did not improve spontaneous activity or pole climbing times compared to untreated PD mice.
- Both PD mice and 4-AP treated PD mice showed reduced midbrain TH expression compared to normal mice; 4-AP did not prevent this reduction.
Conclusions:
- 4-AP pretreatment may reduce the toxicity of MPP+ in cell models.
- 4-AP does not ameliorate motor deficits or protect dopaminergic neurons in MPTP-induced Parkinson's disease models.
- The timing of intervention (pre-treatment vs. post-intervention) is critical for therapeutic efficacy in Parkinson's disease models.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview

